Medical devices, healthcare technology and the business of care
510(k) clearance · K263109

EFAI NEUROSUITE CTA LVO ASSESSMENT SYSTEM (LVO-CTA-100)

Ever Fortune.Ai, Co., Ltd. · Decision date Oct 30, 2026

MEDTECHLEDGER EXPLANATIONK263109

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 10/30/2026 for K263109, the EFAI NEUROSUITE CTA LVO ASSESSMENT SYSTEM (LVO-CTA-100), submitted by Ever Fortune.Ai, Co., Ltd. of Taichung City, Taiwan. The submission was received 09/04/2026 and reviewed under regulation 892.2080 in the Radiology specialty, with product code QAS and the device classification name Radiological Computer-Assisted Triage And Notification Software. This is a 510(k) clearance, not a PMA approval.

The record describes a Traditional 510(k) that was not reviewed by a third party, was not a combination product, and had no authorized Predetermined Change Control Plan. The listed summary is the only linked document; the source does not include the predicate device, the cleared indications for use, or any performance data, so the specific intended use and the basis for substantial equivalence remain unknown from this record.

No clinical, efficacy or patient-selection conclusions are drawn here; those details would reside in the FDA summary document, which was not provided in the source data.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Radiology
Decision date
Oct 30, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K263109
Regulatory pathway
510(k) premarket notification
Product code
QAS
Decision code
SESE
Decision date
Oct 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Radiological Computer-Assisted Triage And Notification Software.

Product code
QAS
FDA device class
2

FDA decision timeline

  1. K263109 received

    Application receipt date recorded by FDA.

  2. K263109 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QAS

Product / regulatory recordCompanyPathwayDecision dateSource
Ischemaview, Inc.510(k) clearanceOct 9, 2026FDA
A2z Radiology Ai, Inc.510(k) clearanceSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ever Fortune.Ai, Co., Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Taichung City

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records